BPC-157: Research Peptide Guide

For research purposes only. This guide describes the chemical identity and laboratory handling of BPC-157 and summarises findings reported in published research. It is not medical advice and does not describe any effect, dose, or use in humans or animals.

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide: a single chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV). It is a partial sequence derived from a protein identified in gastric juice, and is also referred to as PL 14736 or 'stable gastric pentadecapeptide'.

PurePeptides supplies BPC-157 as a lyophilised (freeze-dried) powder at greater than 99% purity, intended strictly as a research-grade reference compound for in-vitro laboratory use. The information on this page describes its chemical identity and laboratory handling only, and must not be interpreted as describing any effect in humans or animals.

BPC-157 is described in the literature as a “stable gastric pentadecapeptide” — a partial sequence of a Body Protection Compound originally identified in gastric juice. Its 15-residue chain (GEPPPGKPADDAGLV) is comparatively stable in aqueous solution, which is one reason it is so frequently used as a reference compound in preclinical tissue-repair and angiogenesis research. In mechanistic terms, the literature most often discusses BPC-157 in connection with angiogenesis (the formation of new blood vessels) and the regulation of growth-factor and nitric-oxide pathways in experimental models.

Chemical identity & specifications

Handling BPC-157 in research protocols

In laboratory settings, lyophilised BPC-157 is typically stored at -20°C, protected from light and moisture, until use. For reconstitution, bacteriostatic water is a commonly cited solvent; once in solution, the material is generally kept refrigerated at 2-8°C with freeze-thaw cycles minimised to preserve peptide integrity.

Researchers quantify BPC-157 by concentration within their experimental system — for example molar concentrations for in-vitro work, or amount-per-mass figures in animal models. These are parameters defined by the study design and reported in the literature; they are not dosing guidance for any human or animal use. To convert between vial mass, solvent volume, and target concentration for laboratory preparation, our peptide reconstitution calculator may be useful.

Findings reported in the research literature

BPC-157 is among the most frequently cited peptides in preclinical tissue-repair research, appearing across in-vitro and animal-model studies. Much of this literature concerns connective-tissue and musculoskeletal models — tendon, ligament, muscle and bone — where it is examined in the context of angiogenesis and cell migration.

Reflecting its origin as a fragment of a protein identified in gastric juice, BPC-157 also features prominently in gastrointestinal-tract research, and it appears in studies touching on neurological and broader systemic pathways in experimental animals. Its comparative stability in solution is one reason it recurs as a synthetic reference compound across these different model systems.

Any effects described in this literature are observations made in controlled experimental systems — cell assays and animal models — and are reported here only to summarise the scientific record. They do not constitute claims about outcomes, efficacy, benefits, or safety in humans, and nothing on this page should be read as encouraging human or animal use. Readers interested in the primary research can review the indexed literature via PubMed’s BPC-157 results.

BPC-157 and TB-500: tissue-repair research peptides

In the research-peptide literature, BPC-157 is frequently discussed alongside TB-500 (synthetic Thymosin Beta-4). Both are studied in models of cell migration, angiogenesis and tissue repair, but they are chemically distinct — different sequences, lengths and biological origins:

For the companion compound, see our TB-500 research guide. Both are supplied by PurePeptides strictly as research materials, with no claim regarding outcomes in humans or animals.

Purity and quality control in research-grade BPC-157

In laboratory research, peptide purity has a direct bearing on reproducibility: synthesis by-products or residual reagents can confound experimental observations. PurePeptides supplies BPC-157 at greater than 99% purity as a lyophilised powder.

In peptide manufacturing, purity is typically assessed by reverse-phase high-performance liquid chromatography (HPLC), while identity is confirmed by mass spectrometry (MS) against the expected molecular weight — approximately 1419.55 g/mol for BPC-157. A certificate of analysis (COA) documenting these results is available on request for the current batch. When evaluating any research-grade peptide, requesting the COA and confirming both the purity figure and the mass-spec identity is good laboratory practice.

Frequently asked questions

Related comparisons

• BPC-157 vs TB-500

Research-grade BPC-157

Greater than 99% purity, lyophilised powder, same-day dispatch before 3PM with tracked UK & EU delivery. Research use only.

Disclaimer: All products supplied by PurePeptides are strictly for laboratory research use only. They are not for human or animal consumption and are not medical products. This guide is informational and summarises publicly available research; it is not medical, clinical, or dosing advice.